Tauriga Sciences, Inc. Focused on Consummating Significant

NEW YORK, NY--(Marketwired - Nov 15, 2017) - Tauriga Sciences, Inc. ( OTC PINK : TAUG ) ("Tauriga" or the "Company"), engaged in the building of life sciences businesses and technologies, today announced its intention to consummate one or more significant acquisition and/or licensing transactions during the calendar year 2018 to both restore and create long term shareholder value. Specifically, Tauriga will evaluate and, where appropriate after a stringent due diligence process, execute on opportunities to expand its business through either the acquisition or the license of products and businesses that offer attractive growth characteristics and/or margins.

The Company expects that its balance sheet and cash position will have been materially strengthened by the end of 2017. As such, the Company's Board of Directors believes the Company will have the resources necessary to consummate acquisition and/or licensing transactions which will provide its stockholders with long-term value. Of course, there can be no guarantee that the Company will be successful in consummating a transaction and, even if it is, whether such a transaction will be successful or result in creating shareholder value or significant revenues.

Tauriga remains committed as well to the commercial launch and of its licensed cupuacu butter lip balm product, branded as "HerMan". The Company will continue its efforts to generate revenue from this product in a complimentary manner to any potential acquisition or licensing activity.

Tauriga's CEO Seth M. Shaw commented, "The Board of Directors believes that the timing is now correct to seriously evaluate potential opportunities with the goal of consummating potential attractive acquisition and licensing transactions during calendar year 2018. The Company wishes to thank its many shareholders for their loyalty exhibited over the past two and half years and management will do its very best to reward its shareholders with a successful long term future."

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. ( OTC PINK : TAUG ) is engaged in building life sciences company through the development, marketing, distribution and potential licensing of a broad array of products and technologies. The Company is presently focused on its upcoming contemplated launch of a Cupacu Butter based lip balm product branded under the name: Herman. The Company has previously disclosed that it plans to launch this product to the retail marketplace during mid-late Autumn of 2017. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. Please visit the Corporate Website at www.tauriga.com

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation: expectations, expects, anticipates, believes, hopes, beliefs, plans and objectives regarding the development, use and marketability of products as well as the attainment of certain corporate goals and milestones (i.e. SEC Periodic Filings, Filing of Proxies, etc.). Such forward-looking statements are based on present circumstances and on Tauriga's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.